{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:02:02Z","timestamp":1789646522664,"version":"4.0.0"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Tumor immunoediting is a dynamic process of interaction between the host immune system and tumor cells and encompasses three sequential phases: elimination, equilibrium, and escape. It plays a central regulatory role in melanoma initiation, progression, and therapeutic response. Currently, increasing attention has been directed toward the complexity of the melanoma tumor microenvironment, in which functional dysregulation of immune cell subsets, imbalance of cytokine networks, and alterations in the metabolic milieu collectively drive the process of immunoediting. However, most existing studies have focused on individual phases or isolated factors, and a comprehensive understanding of the entire immunoediting process and its systematic associations with tumor heterogeneity and resistance to immunotherapy remains insufficient. This review summarizes recent advances in tumor immunoediting within the melanoma tumor microenvironment, with particular emphasis on the regulatory mechanisms through which individual components of the immune microenvironment influence different phases of immunoediting, providing a theoretical basis for optimizing melanoma immunotherapy and identifying novel therapeutic targets.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1946627","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:04:51Z","timestamp":1789643091000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer immunoediting in the melanoma tumor microenvironment: from immune elimination to therapeutic resistance"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaojun","family":"Yan","sequence":"first","affiliation":[{"name":"Department of Dermatology, West China School of Public Health and West China Fourth Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology, Chongqing Rongchang District People\u2019s Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeping","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, Chongqing Rongchang District People's Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Dermatology, West China School of Public Health and West China Fourth Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41572-025-00603-8","article-title":"Cutaneous melanoma","volume":"11","author":"Tasdogan","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00403-024-03758-8","article-title":"The tumor immune microenvironment in primary cutaneous melanoma","volume":"317","author":"Zilberg","year":"2025","journal-title":"Arch Dermatol Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2020.5088","article-title":"Cutaneous melanoma and the immunotherapy revolution (Review)","volume":"57","author":"Leonardi","year":"2020","journal-title":"Int J Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/192719","article-title":"Lessons from cancer immunoediting in cutaneous melanoma","volume":"2012","author":"Aris","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26146778","article-title":"Tumor microenvironment in melanoma-characteristic and clinical implications","volume":"26","author":"Sikorski","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/medicina62040739","article-title":"Uncovering the intricate and heterogeneous cellular microenvironment of cutaneous melanoma","volume":"62","author":"\u021a\u0103poi","year":"2026","journal-title":"Med (Kaunas)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2025.2519066","article-title":"Tumorous cholesterol biosynthesis curtails anti-tumor immunity by preventing MTOR-TFEB-mediated lysosomal degradation of CD274\/PD-L1","volume":"21","author":"Wang","year":"2025","journal-title":"Autophagy"},{"key":"B8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00432-025-06176-z","article-title":"Revealing tumor microenvironment communication through m6A single-cell analysis and elucidating immunotherapeutic potentials for cutaneous melanoma (CM)","volume":"151","author":"Liu","year":"2025","journal-title":"J Cancer Res Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"20617","DOI":"10.1038\/s41598-023-46794-6","article-title":"PTPRC functions as a prognosis biomarker in the tumor microenvironment of cutaneous melanoma","volume":"13","author":"Li","year":"2023","journal-title":"Sci Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-1528209\/v1","article-title":"AURKA is a prognostic potential therapeutic target in skin cutaneous melanoma modulating the tumor microenvironment, apoptosis, and hypoxia","volume":"149","author":"Long","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s00403-024-03080-3","article-title":"Based on scRNA-seq and bulk RNA-seq to establish tumor immune microenvironment-associated signature of skin melanoma and predict immunotherapy response","volume":"316","author":"Li","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"25569","DOI":"10.1038\/s41598-025-10952-9","article-title":"TNFAIP2 deficiency drives formation of an immunosuppressive tumor microenvironment and confers resistance to anti-PD-1 therapy in skin cutaneous melanoma","volume":"15","author":"Wang","year":"2025","journal-title":"Sci Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2023.106850","article-title":"Genes associated with cellular senescence favor melanoma prognosis by stimulating immune responses in tumor microenvironment","volume":"158","author":"Liang","year":"2023","journal-title":"Comput Biol Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054786","article-title":"Acral melanoma is infiltrated with cDC1s and functional exhausted CD8 T cells similar to the cutaneous melanoma of sun-exposed skin","volume":"24","author":"De Leon-Rodr\u00edguez","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7150\/thno.110841","article-title":"X-ray-responsive dissolving microneedles mediate STING pathway activation to potentiate cutaneous melanoma radio-immunotherapy","volume":"15","author":"Hu","year":"2025","journal-title":"Theranostics"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1227648","article-title":"Impaired activation of plasmacytoid dendritic cells via toll-like receptor 7\/9 and STING is mediated by melanoma-derived immunosuppressive cytokines and metabolic drift","volume":"14","author":"Monti","year":"2023","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s00432-023-05580-7","article-title":"The fatty acid-related gene signature stratifies poor prognosis patients and characterizes TIME in cutaneous melanoma","volume":"150","author":"Hua","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28104018","article-title":"Tremella fuciformis polysaccharide induces apoptosis of B16 melanoma cells via promoting the M1 polarization of macrophages","volume":"28","author":"Xie","year":"2023","journal-title":"Molecules"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2024.150153","article-title":"Nanoengineered M1 macrophages enhance photodynamic therapy of melanoma through oxygen production and subsequent antitumor immunity","volume":"487","author":"Zhang","year":"2024","journal-title":"Chem Eng J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s13046-024-03182-w","article-title":"Cell therapy using ex vivo reprogrammed macrophages enhances antitumor immune responses in melanoma","volume":"43","author":"NooNepalle","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2024.09.011","article-title":"Programmed death ligand-1 in melanoma and extracellular vesicles promotes local and regional immune suppression through M2-like macrophage polarization","volume":"195","author":"Huang","year":"2025","journal-title":"Am J Pathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000374","article-title":"PMEL as a prognostic biomarker and negatively associated with immune infiltration in skin cutaneous melanoma (SKCM)","volume":"44","author":"Zhang","year":"2021","journal-title":"J Immunother"},{"key":"B23","doi-asserted-by":"publisher","first-page":"20460","DOI":"10.1038\/s41598-022-24353-9","article-title":"C1QA, C1QB, and GZMB are novel prognostic biomarkers of skin cutaneous melanoma relating tumor microenvironment","volume":"12","author":"Liang","year":"2022","journal-title":"Sci Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"9164","DOI":"10.1038\/s41598-021-88676-9","article-title":"A novel prognostic biomarker LCP2 correlates with metastatic melanoma-infiltrating CD8(+) T cells","volume":"11","author":"Wang","year":"2021","journal-title":"Sci Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adi9517","article-title":"CD4(+) T cell immunity against cutaneous melanoma encompasses multifaceted MHC II-dependent responses","volume":"9","author":"Bawden","year":"2024","journal-title":"Sci Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004095","article-title":"Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation","volume":"10","author":"Wang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12935-020-01271-2","article-title":"Identification of immune-related biomarkers associated with tumorigenesis and prognosis in cutaneous melanoma patients","volume":"20","author":"Huang","year":"2020","journal-title":"Cancer Cell Int"},{"key":"B28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejca.2021.03.053","article-title":"Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma","volume":"151","author":"Zhu","year":"2021","journal-title":"Eur J Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2174\/0115680266416033250731102049","article-title":"Preliminary study on GZMA- and GSDMB-associated pyroptosis and CD8+ T cell-mediated immune evasion in skin cutaneous melanoma","volume":"26","author":"Chen","year":"2026","journal-title":"Curr Top Med Chem"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.16296","article-title":"SOX10 inhibits T cell recognition by inducing expression of the immune checkpoint molecule PD-L1 in A375 melanoma cells","volume":"43","author":"Sasaki","year":"2023","journal-title":"Anticancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1590\/0001-3765202420230441","article-title":"Density of high endothelial venules and PDL-1 expression: relationship with tumor-infiltrating lymphocytes in primary cutaneous melanomas","volume":"96","author":"Stolfo","year":"2024","journal-title":"Acad Bras Cienc"},{"key":"B32","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12935-024-03278-5","article-title":"Dormancy of cutaneous melanoma","volume":"24","author":"Singvogel","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.64898\/2025.12.11.692633","article-title":"Mechanisms of tumor persistence in metastatic melanoma following successful immunotherapy","author":"Shi","year":"2025","journal-title":"bioRxiv"},{"key":"B34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.canlet.2020.01.016","article-title":"Dormant tumor cells interact with memory CD8(+) T cells in RET transgenic mouse melanoma model","volume":"474","author":"Flores-Guzm\u00e1n","year":"2020","journal-title":"Cancer Lett"},{"key":"B35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12943-025-02294-x","article-title":"Dual role of interferon-gamma in the response of melanoma patients to immunotherapy with immune checkpoint inhibitors","volume":"24","author":"Wawrzyniak","year":"2025","journal-title":"Mol Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009410","article-title":"IFN\u03b3 mediates the resistance of tumor cells to distinct NK cell subsets","volume":"12","author":"Hofman","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ccell.2025.01.009","article-title":"Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma","volume":"43","author":"Schiantarelli","year":"2025","journal-title":"Cancer Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00722-9","article-title":"Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer","volume":"12","author":"Kim","year":"2020","journal-title":"Genome Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2020.02.006","article-title":"ADORA1 inhibition promotes tumor immune evasion by regulating the ATF3-PD-L1 axis","volume":"37","author":"Liu","year":"2020","journal-title":"Cancer Cell"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009435","article-title":"Anti-PD-1 amplifies costimulation in melanoma-infiltrating T(h)1-like Foxp3(+) regulatory T cells to alleviate local immunosuppression","volume":"13","author":"Attias","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"110093","DOI":"10.1007\/978-3-319-45147-3_105","article-title":"To be or not to Be\": Regulatory T cells in melanoma","volume":"118","author":"Ibrahim","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41467-019-14218-7","article-title":"Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1","volume":"11","author":"Imbert","year":"2020","journal-title":"Nat Commun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s414882","article-title":"Defeating melanoma through a nano-enabled revision of hypoxic and immunosuppressive tumor microenvironment","volume":"18","author":"Yang","year":"2023","journal-title":"Int J Nanomedicine"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-024-09930-y","article-title":"Lactate secreted by glycolytic conjunctival melanoma cells attracts and polarizes macrophages to drive angiogenesis in zebrafish xenografts","volume":"27","author":"Yin","year":"2024","journal-title":"Angiogenesis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020464","article-title":"Melanoma-derived exosomal miR-125b-5p educates tumor associated macrophages (TAMs) by targeting lysosomal acid lipase A (LIPA)","volume":"12","author":"Gerloff","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012102","article-title":"Cancer-associated fibroblasts: activin A adds another string to their bow","volume":"12","author":"Samain","year":"2020","journal-title":"EMBO Mol Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-23-0757","article-title":"Melanoma clonal heterogeneity leads to secondary resistance after adoptive cell therapy with tumor-infiltrating lymphocytes","volume":"12","author":"K\u00f6nig","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-23-0099","article-title":"HLA class II loss and JAK1\/2 deficiency coevolve in melanoma leading to CD4 T-cell and IFN\u03b3 cross-resistance","volume":"29","author":"Stupia","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03840-7","article-title":"PMN-MDSCs are responsible for immune suppression in anti-PD-1 treated TAP1 defective melanoma","volume":"27","author":"Zhang","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0274897","article-title":"HLA-DRB1: a new potential prognostic factor and therapeutic target of cutaneous melanoma and an indicator of tumor microenvironment remodeling","volume":"17","author":"Deng","year":"2022","journal-title":"PloS One"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-21-1463","article-title":"Enhancing PD-L1 degradation by ITCH during MAPK inhibitor therapy suppresses acquired resistance","volume":"12","author":"Yang","year":"2022","journal-title":"Cancer Discov"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6195","article-title":"Immune-independent acquired resistance to PD-L1 antibody initiated by PD-L1 upregulation via PI3K\/AKT signaling can be reversed by anlotinib","volume":"12","author":"Gao","year":"2023","journal-title":"Cancer Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-19-2914","article-title":"A feed-forward mechanosignaling loop confers resistance to therapies targeting the MAPK pathway in BRAF-mutant melanoma","volume":"80","author":"Girard","year":"2020","journal-title":"Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1038\/s41467-024-46422-5","article-title":"Mi-2\u03b2 promotes immune evasion in melanoma by activating EZH2 methylation","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2024.100319","article-title":"DNA methyltransferase inhibition upregulates the costimulatory molecule ICAM-1 and the immunogenic phenotype of melanoma cells","volume":"5","author":"Cereghetti","year":"2025","journal-title":"JID Innov"},{"key":"B56","doi-asserted-by":"publisher","first-page":"34","DOI":"10.21037\/cco-25-9","article-title":"Chemoresistance in cutaneous melanoma: contemporary and future aspects","volume":"14","author":"Nigam","year":"2025","journal-title":"Chin Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2025.06.021","article-title":"A biomimetic nanoplatform mediates hypoxia-adenosine axis disruption and PD-L1 knockout for enhanced MRI-guided chemodynamic-immunotherapy","volume":"201","author":"Sun","year":"2025","journal-title":"Acta Biomater"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-22-0896","article-title":"ANXA1 promotes tumor immune evasion by binding PARP1 and upregulating Stat3-induced expression of PD-L1 in multiple cancers","volume":"11","author":"Xiao","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061697","article-title":"T cell immunoglobulin and mucin domain 3 (TIM-3) in cutaneous melanoma: a narrative review","volume":"15","author":"Cazzato","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B60","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1186\/s12885-021-08385-4","article-title":"The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in Malignant melanoma - an immunohistochemical study","volume":"21","author":"Salmi","year":"2021","journal-title":"BMC Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/ph18081082","article-title":"Tumor microenvironmental dynamics in shaping resistance to therapeutic interventions in melanoma: a narrative review","volume":"18","author":"Turner","year":"2025","journal-title":"Pharm (Basel)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1016\/j.cell.2024.07.016","article-title":"LAG-3 and PD-1 synergize on CD8(+) T cells to drive T cell exhaustion and hinder autocrine IFN-\u03b3-dependent anti-tumor immunity","volume":"187","author":"Andrews","year":"2024","journal-title":"Cell"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202520634","article-title":"T cell exhaustion in cancer immunotherapy: heterogeneity, mechanisms, and therapeutic opportunities","volume":"13","author":"Yu","year":"2026","journal-title":"Adv Sci (Weinh)"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01159-y","article-title":"Mitochondrial oxidative phosphorylation in cutaneous melanoma","volume":"124","author":"Kumar","year":"2021","journal-title":"Br J Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adk7399","article-title":"Activation and antitumor immunity of CD8(+) T cells are supported by the glucose transporter GLUT10 and disrupted by lactic acid","volume":"16","author":"Liu","year":"2024","journal-title":"Sci Transl Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102802","article-title":"Targeting tumour metabolism in melanoma to enhance response to immune checkpoint inhibition: a balancing act","volume":"129","author":"Tiersma","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-025-02273-5","article-title":"Single-cell transcriptomics reveals hypoxia-driven iCAF_PLAU is associated with stemness and immunosuppression in anorectal Malignant melanoma","volume":"60","author":"Zhang","year":"2025","journal-title":"J Gastroenterol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-026-08201-2","article-title":"Single-cell profiling uncovers a hypoxia-vascular-immune axis underlying poor immunotherapy response in acral versus cutaneous melanoma","volume":"24","author":"Dong","year":"2026","journal-title":"J Transl Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1038\/s41467-024-47425-y","article-title":"Molecular patterns of resistance to immune checkpoint blockade in melanoma","volume":"15","author":"Lauss","year":"2024","journal-title":"Nat Commun"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.70027","article-title":"Comprehensive profiling of acral lentiginous melanoma reveals downregulated immune activation compared to cutaneous melanoma","volume":"38","author":"Wang","year":"2025","journal-title":"Pigment Cell Melanoma Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"105308","DOI":"10.2139\/ssrn.4805810","article-title":"Single-cell RNA sequencing reveals melanoma cell state-dependent heterogeneity of response to MAPK inhibitors","volume":"107","author":"Lim","year":"2024","journal-title":"EBioMedicine"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1172\/jci171063","article-title":"The CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma","volume":"134","author":"Wu","year":"2024","journal-title":"J Clin Invest"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.967277","article-title":"Identification of fatty acid metabolism-related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2024.102365","article-title":"Co-delivery of STING and TLR7\/8 agonists in antigen-based nanocapsules to dendritic cells enhances CD8+ T cell-mediated melanoma remission","volume":"57","author":"Schunke","year":"2024","journal-title":"Nano Today"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00889-9","article-title":"Systemic IFN-I combined with topical TLR7\/8 agonists promotes distant tumor suppression by c-Jun-dependent IL-12 expression in dendritic cells","volume":"6","author":"Sanlorenzo","year":"2025","journal-title":"Nat Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1155\/humu\/8907583","article-title":"YIF1B mutational dysregulation drives cutaneous melanoma progression by remodeling the TME","volume":"2026","author":"Wang","year":"2026","journal-title":"Hum Mutat"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1093\/jimmun\/vkaf131","article-title":"STING agonists drive recruitment and intrinsic type I interferon responses in monocytic lineage cells for optimal anti-tumor immunity","volume":"214","author":"Girard","year":"2025","journal-title":"J Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.3c01310","article-title":"Mannosylated STING agonist drugamers for dendritic cell-mediated cancer immunotherapy","volume":"10","author":"Nguyen","year":"2024","journal-title":"ACS Cent Sci"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae248","article-title":"Real-world treatment patterns and outcomes of patients with advanced melanoma treated with nivolumab plus relatlimab","volume":"29","author":"Thakker","year":"2024","journal-title":"Oncologist"},{"key":"B80","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/nejmoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/s41467-025-56392-x","article-title":"MCT1 lactate transporter blockade re-invigorates anti-tumor immunity through metabolic rewiring of dendritic cells in melanoma","volume":"16","author":"Niveau","year":"2025","journal-title":"Nat Commun"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1428802","article-title":"Metabolic modulation of melanoma enhances the therapeutic potential of immune checkpoint inhibitors","volume":"14","author":"Gurel","year":"2024","journal-title":"Front Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00721-w","article-title":"Mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade response in melanoma","volume":"5","author":"Mahmood","year":"2024","journal-title":"Nat Cancer"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1101\/2025.08.24.671992","article-title":"Decitabine reverses innate immune gene suppression in rare melanomas","author":"MacBeth","year":"2026","journal-title":"Mol Cancer Ther"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.32604\/or.2025.063843","article-title":"Tumor vaccines for Malignant melanoma: progress, challenges, and future directions","volume":"33","author":"Luo","year":"2025","journal-title":"Oncol Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5c04580","article-title":"Oxygen-generating transdermal nanoplatform codelivering BRD4 proteolysis-targeting chimera\/verteporfin\/CaO(2) synergistically remodels immunosuppressive melanoma microenvironment to potentiate combination immunotherapy","volume":"19","author":"Wei","year":"2025","journal-title":"ACS Nano"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2022.09.029","article-title":"Reshaping hypoxia and silencing CD73 via biomimetic gelatin nanotherapeutics to boost immunotherapy","volume":"351","author":"Yuan","year":"2022","journal-title":"J Control Release"},{"key":"B88","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12951-025-03851-8","article-title":"Melanoma treatment in the era of nanotechnology and precision medicine","volume":"24","author":"da Cruz","year":"2025","journal-title":"J Nanobiotechnol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1946627\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:04:52Z","timestamp":1789643092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1946627\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":88,"alternative-id":["10.3389\/fimmu.2026.1946627"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1946627","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"article-number":"1946627"}}